Results Announced from Phase 2 Myelin Repair Trial in Relapsing MS
June 7, 2016
Biogen announced results from a Phase 2 clinical trial of anti-LINGO (opicinumab), an approach to repair myelin, the nerve-insulating casing damaged in multiple sclerosis. According to the company’s press release, the trial did not meet its primary endpoint, which was improvement in measures of physical function (including walking, upper limb coordination), cognitive function, or disability. The trial involved 418 people with relapsing MS (including relapsing-remitting and secondary-progressive MS) who were taking interferon beta-1a (Avonex) plus one of several doses of intravenous opicinumab or placebo for 72 weeks.
The company is still evaluating results from the extensive testing and monitoring that occurred during the trial to help determine next steps for testing opicinumab in the future. The findings are likely to inform and enhance the design of future trials of myelin repair strategies in people with MS.
Additional myelin repair strategies for MS are undergoing laboratory research and clinical trials, including a trial recruiting people nationwide who are experiencing a relapse
Another Phase 2 clinical trial of anti-LINGO was positive. It involved people who had experienced optic neuritis, which is often the first clinical episode of MS. Read more
Read more about the trial results in Genetic Engineering & Biotechnology News
Read more about research to repair the nervous system in MS